PBYI - Puma Biotechnology, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 10.53 |
| Open | 10.76 |
| Bid | 10.71 x 800 |
| Ask | 11.10 x 800 |
| Day's Range | 10.44 - 10.99 |
| 52 Week Range | 5.50 - 15.00 |
| Volume | 742,353 |
| Avg. Volume | 1,079,930 |
| Market Cap | 421.593M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.12 |
| Earnings Date | Aug 06, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.11 |
- Insider Monkey
Should You Buy Puma Biotechnology Inc (PBYI)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- Zacks
Why the Sell-Off in These 5 Stocks is a Buying Opportunity
We have zeroed in on five stocks that have witnessed a slump this past week but have a favorable Zacks Rank 1 (Strong Buy) or 2 (Buy).
- Thomson Reuters StreetEvents
Edited Transcript of PBYI earnings conference call or presentation 7-May-20 8:30pm GMT
Q1 2020 Puma Biotechnology Inc Earnings Call
- Zacks
Puma Biotech (PBYI) Up 7.5% Since Last Earnings Report: Can It Continue?
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology reports inducement awards for the month of May granted under Nasdaq Listing Rule 5635(c)(4).
- Zacks
Moving Average Crossover Alert: Puma Biotechnology
Puma Biotechnology, Inc. (PBYI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks
Puma Biotechnology, Inc. (PBYI) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Puma Biotechnology, Inc. (PBYI).
- Zacks
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.
- Simply Wall St.
Analysts Have Made A Financial Statement On Puma Biotechnology, Inc.'s (NASDAQ:PBYI) First-Quarter Report
Puma Biotechnology, Inc. (NASDAQ:PBYI) defied analyst predictions to release its first-quarter results, which were...
- Motley Fool
Puma Biotechnology Inc (PBYI) Q1 2020 Earnings Call Transcript
Good afternoon, and welcome to Puma's conference call to discuss our financial results for the first quarter of 2020. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of Puma Biotechnology; and Maximo Nougues, Chief Financial Officer.
- Zacks
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of 45.57% and 16.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Puma Biotechnology Reports First Quarter 2020 Financial Results
Puma Biotechnology released its financial results for the first quarter ended March 31, 2020 on May 7, 2020.
- Business Wire
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Puma Biotechnology's licensing partner CANbridge Pharmaceuticals has received regulatory approval to market NERLYNX (neratinib) in Mainland China.
- Business Wire
Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the BofA Securities Virtual 2020 Health Care Conference on May 13, 2020.
- Business Wire
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Puma Biotechnology and Bixink Therapeutics have signed a license agreement in which Bixink will commercialize Puma's drug NERLYNX in South Korea.
- Investor's Business Daily
Puma Biotechnology Earns 90 RS Rating, Edging Above 10-Week Line
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Puma Biotechnology, which saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 75 to 90. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
- Simply Wall St.
Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven?
Puma Biotechnology, Inc.'s (NASDAQ:PBYI): Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the...
- GlobeNewswire
Seasoned Biotech Financial Executive, Jay M. Moyes, Joins Sera Prognostics
Sera Prognostics, Inc., The Pregnancy Companyâ„¢, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes as Chief Financial Officer. Mr. Moyes joins Sera Prognostics as it transitions from rigorous scientific and groundbreaking clinical stage company into a rapidly growing commercial organization. For more than two decades, Jay Moyes has served in C-level executive and board positions of both private and public companies.
- Business Wire
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
On March 25, 2020, Puma Biotechnology reported an inducement award granted to Jeff Ludwig as part of his agreement to enter into employment with Puma.
- Yahoo Finance Video
What to expect from Nike earnings as coronavirus impacts retail
Retailers are facing a variety of issues from weaker in-store sales to laying off workers. Yahoo Finance’s Reggie Wade joins the On The Move panel to discuss what investors should expect ahead of Nike's earnings report.
- Simply Wall St.
Puma Biotechnology, Inc. Just Released Its Yearly Earnings: Here's What Analysts Think
Shareholders of Puma Biotechnology, Inc. (NASDAQ:PBYI) will be pleased this week, given that the stock price is up 11...
- Thomson Reuters StreetEvents
Edited Transcript of PBYI earnings conference call or presentation 20-Feb-20 9:30pm GMT
Q4 2019 Puma Biotechnology Inc Earnings Call
- Benzinga
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
- Benzinga
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ...
